Overview
My clinical and research interests are in the diagnosis and treatment of breast cancer. I am interested in clinical trial development and investigation of novel or new treatment options for patients with breast cancer. I am also interested in improving access to clinical trials to diverse patient populations.
Current Appointments & Affiliations
Assistant Professor of Medicine
·
2022 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Genomic and transcriptomic landscape of HER2-low breast cancer.
Journal Article Breast Cancer Res Treat · January 2025 BACKGROUND: Novel agents have expanded the traditional HER2 definitions to include HER2-Low (HER2L) Breast Cancer (BC). We sought to evaluate the distinct molecular characteristics of HER2L BC to understand potential clinical/biologic factors driving resis ... Full text Link to item CiteBlood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.
Journal Article Commun Med (Lond) · December 2, 2024 BACKGROUND: Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, including in these "cold tumors". In clinica ... Full text Link to item CiteGenomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.
Journal Article JCO Precis Oncol · December 2024 PURPOSE: Malignant phyllodes tumors (MPTs) are rare fibroepithelial tumors of the breast with aggressive biologic behavior and high recurrence rates. Surgery remains the primary treatment modality for these tumors; however, initial investigations suggest a ... Full text Link to item CiteRecent Grants
A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician's choice chemo, for the treatment of participants with metastatic HER2-positive breast cancer
Clinical TrialPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2025 - 2030A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer with Resist...
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2024 - 2029A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembroliz
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2024 - 2029View All Grants
Education, Training & Certifications
Boston University, School of Medicine ·
2016
M.D.